Summary: <br> <a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.talkingbiotechpodcast.com%2F211-car-t-cells-engineered-to-attack-cancer%2F&via=talkingbiotech" class="twitter-share-button" data-size="large">Tweet</a><br> <a href="https://i0.wp.com/www.talkingbiotechpodcast.com/wp-content/uploads/2019/11/211-fraietta-cover.jpg"></a><br> Can we use genetic engineering to help the body’s immune system target cancer cells? This is exactly what happens with CAR-T (chimeric antigen receptor) T-cell therapy. CAR-T cells are T-cells, immune cells of the body that are reprogrammed to identify specific surface signatures that define specific types of cancer cells. It allows these immune agents to seek and destroy cancer cells with great accuracy and with fewer side effects to traditional chemotherapy or radiation. While in their infancy, these techniques show great promise for future therapies. Today’s guest is Dr. Joe Fraietta, a leader in CAR-T cell solutions. He explains how the technology works, describes its applications and future uses.<br> <br>
